Targeting TGF-β and, to a lesser degree, Hh signaling, has been considered a promising therapeutic approach for HCC since their inhibition can reduce tumor growth, increase sensitivity to other therapies, and improve clinical outcomes [51]. The gene discussed is TGFB1; the disease is neoplasm.